ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
aspaveli
swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxysmal - imunosupresivi - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.
ciprinol 250 mg/1 tableta filmom obložena tableta
krka farma d.o.o. sarajevo - ciprofloksacin - filmom obložena tableta - 250 mg/1 tableta - 1 filmom obložena tableta sadrži: 250 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorid, monohidrata)
ciprinol 500 mg/1 tableta filmom obložena tableta
krka farma d.o.o. sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorid, monohidrata)
cipromed 500 mg/1 tableta filmom obložena tableta
pliva d.o.o.sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorida)
cipromed 500 mg/1 tableta filmom obložena tableta
pliva d.o.o.sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorida)
azaran 1 g/1 viala prašak za rastvor za injekciju/infuziju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - ceftriakson - prašak za rastvor za injekciju/infuziju - 1 g/1 viala - 1 bočica sa praškom za rastvor za injekciju/infuziju sadrži: 1 g ceftriakson (u obliku ceftriaksondinatrijum, triseskvihidrata)
cipromed 500 mg/1 tableta filmom obložena tableta
pliva d.o.o.sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacina (u obliku ciprofloksacinhidrohlorida)
clopidogrel/acetylsalicylic acid zentiva (previously duocover)
sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotska sredstva - akutna koronarna infarkt syndromemyocardial .
ampicilin alkaloid 250 mg/5 ml prašak za oralnu suspenziju
alkaloid d.o.o. sarajevo - ampicilin - prašak za oralnu suspenziju - 250 mg/5 ml - 5 ml oralne suspenzije sadrži 250 mg ampicilin (u obliku ampicilin, trihidrata)